-

Masimo to Present in the Wells Fargo Healthcare Conference

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management will participate in the Wells Fargo Healthcare Conference on Thursday, Sept 4, 2025 at 1:30 p.m. Eastern time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation.

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve life, improve patient outcomes, reduce the cost of care, and take noninvasive monitoring to new sites and applications. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown to outperform other pulse oximetry technologies in over 100 independent and objective studies, which can be found at www.masimo.com/evidence/featured-studies/feature. Masimo SET® is estimated to be used on more than 200 million patients around the world each year and is the primary pulse oximetry at all 10 top U.S. hospitals as ranked in the 2025 Newsweek World’s Best Hospitals listing. Additional information about Masimo and its products may be found at www.masimo.com.

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI and ORI are trademarks or registered trademarks of Masimo Corporation

Contacts

Investor Contact:
Eli Kammerman
(949) 297-7077
ekammerman@masimo.com 

Media Contact:
Evan Lamb

(949) 396-3376 
elamb@masimo.com

Masimo

NASDAQ:MASI

Release Versions

Contacts

Investor Contact:
Eli Kammerman
(949) 297-7077
ekammerman@masimo.com 

Media Contact:
Evan Lamb

(949) 396-3376 
elamb@masimo.com

More News From Masimo

Masimo O3® Regional Oximetry Receives FDA Clearance for Expanded Indication of Its Unique Delta Hemoglobin Parameters

IRVINE, Calif.--(BUSINESS WIRE)--Masimo O3®'s delta hemoglobin parameters have received FDA clearance for cerebral and somatic applications and all patient populations....

Masimo Reports Second Quarter 2025 Results

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI) today announced its financial results for the second quarter ended June 28, 2025. Second Quarter 2025 Results From Continuing Operations(1): GAAP revenue of $371 million, representing 8% growth on a reported basis; Non-GAAP revenue of $370 million, representing 7% growth on a constant currency basis(2); GAAP net income per diluted share of $0.82; and Non-GAAP net income per diluted share(2) of $1.33, which grew 46% versus prior...

Masimo to Report Second Quarter 2025 Financial Results after Market Close on Tuesday, August 5

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) will release second quarter 2025 financial results for the period ended June 28, 2025, after the market closes on Tuesday, August 5, 2025. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Katie Szyman, Chief Executive Officer, and Micah Young, Chief Financial Officer. To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each...
Back to Newsroom